The Role of Bone Grafting vs. Bone Cement in the Treatment of Giant Cell Tumor of Bone: A Systematic Review and Meta-Analysis on the Risk of Recurrence in 1,454 Patients.
Journal
JBJS reviews
ISSN: 2329-9185
Titre abrégé: JBJS Rev
Pays: United States
ID NLM: 101674872
Informations de publication
Date de publication:
01 Sep 2024
01 Sep 2024
Historique:
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
epublish
Résumé
Giant cell tumor of bone (GCTB) presents a challenge in management due to its invasive nature and propensity for local recurrence. While either bone grafting (BG) or bone cement (BC) can be utilized to fill defects after intralesional curettage, the optimal treatment remains contested. The purpose of this study was to examine the impact of defect filling with BC compared with BG on recurrence rates in patients with GCTB following intralesional curettage. A random-effects model binary outcome meta-analysis was performed utilizing recurrence rate for the BC and BG groups to evaluate the risk ratio (p < 0.05 considered significant). There were 1,454 patients included. Intralesional curettage with BG had a recurrence risk ratio of 1.68 (95% confidence interval [CI], 1.22-2.31, p = 0.001) when compared with BC. The overall rate of recurrence for GCTB after intralesional curettage with BC was 20.05% vs. 29.74% with BG (95% CI, 0.17-0.23 vs. 0.26-0.33, p < 0.001). Intralesional curettage with BC for the treatment of GCTB demonstrated lower recurrence rates than intralesional curettage with BG. However, the rates of recurrence remain substantial for both groups, necessitating careful consideration of the benefits and potential pitfalls associated with BC vs. BG when considering salvage options after recurrences. Level III. See Instructions for Authors for a complete description of levels of evidence.
Sections du résumé
BACKGROUND
BACKGROUND
Giant cell tumor of bone (GCTB) presents a challenge in management due to its invasive nature and propensity for local recurrence. While either bone grafting (BG) or bone cement (BC) can be utilized to fill defects after intralesional curettage, the optimal treatment remains contested. The purpose of this study was to examine the impact of defect filling with BC compared with BG on recurrence rates in patients with GCTB following intralesional curettage.
METHODS
METHODS
A random-effects model binary outcome meta-analysis was performed utilizing recurrence rate for the BC and BG groups to evaluate the risk ratio (p < 0.05 considered significant). There were 1,454 patients included.
RESULTS
RESULTS
Intralesional curettage with BG had a recurrence risk ratio of 1.68 (95% confidence interval [CI], 1.22-2.31, p = 0.001) when compared with BC. The overall rate of recurrence for GCTB after intralesional curettage with BC was 20.05% vs. 29.74% with BG (95% CI, 0.17-0.23 vs. 0.26-0.33, p < 0.001).
CONCLUSION
CONCLUSIONS
Intralesional curettage with BC for the treatment of GCTB demonstrated lower recurrence rates than intralesional curettage with BG. However, the rates of recurrence remain substantial for both groups, necessitating careful consideration of the benefits and potential pitfalls associated with BC vs. BG when considering salvage options after recurrences.
LEVEL OF EVIDENCE
METHODS
Level III. See Instructions for Authors for a complete description of levels of evidence.
Identifiants
pubmed: 39236154
doi: 10.2106/JBJS.RVW.24.00080
pii: 01874474-202409000-00005
doi:
Substances chimiques
Bone Cements
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by The Journal of Bone and Joint Surgery, Incorporated.
Déclaration de conflit d'intérêts
Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSREV/B140).
Références
Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol. 2006;29(1):96-9.
Jamshidi K, Karimi A, Mirzaei A. Epidemiologic characteristics, clinical behavior, and outcome of the giant cell tumor of the bone: a retrospective single-center study. Arch Bone Jt Surg. 2019;7(6):538-44.
Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors. 2009;1(2):159-63.
Schajowicz F, Granato DB, McDonald DJ, Sundaram M. Clinical and radiological features of atypical giant cell tumours of bone. Br J Radiol. 2014;64(766):877-89.
Feigenberg SJ, Marcus RB Jr, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res. 2003;411:207-16.
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res. 2011;469(4):1181-7.
Knochentumoren A. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am. 2008;90(5):1060-7.
Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):969-78.
Blackley H, Wunder J, Davis A, White L, Kandel R, Bell R. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am. 1999;81(6):811-20.
Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P, Follerås G. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008;79(1):86-93.
Futamura N, Urakawa H, Tsukushi S, Arai E, Kozawa E, Ishiguro N, Nishida Y. Giant cell tumor of bone arising in long bones possibly originates from the metaphyseal region. Oncol Lett. 2016;11(4):2629-34.
Ambrosi F, Righi A, Benini S, Magagnoli G, Chiaramonte I, Manfrini M, Gasbarrini A, Frisoni T, Gambarotti M. Giant cell tumor of bone in patients under 16 years old: a single-institution case series. Cancers. 2021;13(11):2585.
McGough RL, Rutledge J, Lewis VO, Lin PP, Yasko AW. Impact severity of local recurrence in giant cell tumor of bone. Clin Orthop Relat Res. 2005;438:116-22.
Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Surg. 2013;21(2):118-26.
Leinauer B, Wolf E, Werner M, Baumhoer D, Breining T, Luebke AM, Maas R, Schultheiß M, von Baer A, Sufi-Siavach A, Moritz C, Geißler S, Mellert K, Möller P, Barth TFE, Jundt G. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases. Histopathology. 2021;79(5):720-30.
Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9-24.
Balke M, Ahrens H, Streitbuerger A, Koehler G, Winkelmann W, Gosheger G, Hardes J. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol. 2009;135(1):149-58.
Prosser G, Baloch K, Tillman R, Carter S, Grimer R. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res. 2005;435:211-8.
Zhang S, Zhang J, Wang X. Comparison of tumor curettage and resection for treatment of giant cell tumor of the bone around the knee joint. Pak J Med Sci. 2016;32(3):662-6.
Zhou L, Tang J, Shen L, Zhang Z, Yuan T. Giant cell tumors of the distal ulna: long-term recurrence rate and functional outcomes of en bloc resection versus curettage in a multicenter study. J Orthop Surg Res. 2023;18(1):743.
Tsukamoto S, Mavrogenis AF, Kido A, Errani C. Current concepts in the treatment of giant cell tumors of bone. Cancers. 2021;13(15):3647.
Tsukamoto S, Mavrogenis AF, Akahane M, Honoki K, Kido A, Tanaka Y, Donati DM, Errani C. Risk factors of fracture following curettage for bone giant cell tumors of the extremities. BMC Musculoskelet Disord. 2022;23(1):477.
van der Heijden L, Dijkstra PDS, Campanacci DA, Gibbons CLMH, van de Sande MA. Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res. 2013;471(3):820-9.
Vult von Steyern F, Bauer H, Trovik C, Kivioja A, Bergh P, Holmberg Jörgensen P, Follerås G, Rydholm A; Scandinavian Sarcoma Group. Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing: a Scandinavian Sarcoma Group study. J Bone Joint Surg Br. 2006;88(4):531-5.
Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM; Canadian Sarcoma Group. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res. 2002;397(397):248-58.
Machak GN, Snetkov AI. The impact of curettage technique on local control in giant cell tumour of bone. Int Orthop. 2021;45(3):779-89.
Pogrel M, Regezi J, Fong B, Hakim-Faal Z, Rohrer M, Tran C, Schiff T. Effects of liquid nitrogen cryotherapy and bone grafting on artificial bone defects in minipigs: a preliminary study. Int J Oral Maxillofac Surg. 2002;31(3):296-302.
Hasan BZ, Mesregah MK. A technical note on autologous iliac crest bone grafting for restoration of the distal tibial articular surface. J Exp Orthop. 2023;10(1):50.
Ghert MA, Rizzo M, Harrelson JM, Scully SP. Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res. 2002;400:201-10.
Wang Y, Tian Q, Wu C, Li H, Li J, Feng Y. Management of the cavity after removal of giant cell tumor of the bone. Front Surg. 2021;8:626272.
Mjöberg B, Pettersson H, Rosenqvist R, Rydholm A. Bone cement, thermal injury and the radiolucent zone. Acta Orthop Scand. 1984;55(6):597-600.
Radev BR, Kase JA, Askew MJ, Weiner SD. Potential for thermal damage to articular cartilage by PMMA reconstruction of a bone cavity following tumor excision: a finite element study. J Biomech. 2009;42(8):1120-6.
Hisatome T, Yasunaga Y, Ikuta Y, Fujimoto Y. Effects on articular cartilage of subchondral replacement with polymethylmethacrylate and calcium phosphate cement. J Biomed Mater Res. 2002;59(3):490-8.
Wechsler C, Hodel S, Stern C, Laux CJ, Rosskopf AB, Müller DA. Articular degeneration after subchondral cementation for giant cell tumors at the knee. Surg Oncol. 2022;44:101817.
Caubère A, Harrosch S, Fioravanti M, Curvale G, Rochwerger A, Mattei JC. Does curettage–cement packing for treating giant cell tumors at the knee lead to osteoarthritis? Orthopa Traumatol Surg Res. 2017;103(7):1075-9.
Xu HR, Niu XH, Zhang Q, Hao L, Ding Y, Li Y. Subchondral bone grafting reduces degenerative change of knee joint in patients of giant cell tumor of bone. Chin Med J. 2013;126(16):3053-6.
Fraquet N, Faizon G, Rosset P, Phillipeau JM, Waast D, Gouin F. Long bones giant cells tumors: treatment by curettage and cavity filling cementation. Orthop Traumatol Surg Res. 2009;95(6):402-6.
de Monès E, Schlaubitz S, Oliveira H, d'Elbée JM, Bareille R, Bourget C, Couraud L, Fricain JC. Comparative study of membranes induced by PMMA or silicone in rats, and influence of external radiotherapy. Acta Biomater. 2015;19:119-27.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
Larios F, Gonzalez MR, Ruiz-Arellanos K, Aquilino E Silva G, Pretell-Mazzini J. Is unplanned excision of soft tissue sarcomas associated with worse oncological outcomes? A systematic review and meta-analysis. Cancers. 2024;16(2):443.
Aoude A, Nikomarov D, Perera JR, Ibe IK, Griffin AM, Tsoi KM, Ferguson PC, Wunder JS. Giant cell tumour of bone. Bone Joint J. 2023;105-B(5):559-67.
Benevenia J, Rivero SM, Moore J, Ippolito JA, Siegerman DA, Beebe KS, Patterson FR. Supplemental bone grafting in giant cell tumor of the extremity reduces nononcologic complications. Clin Orthop Relat Res. 2017;475(3):776-83.
Errani C, Tsukamoto S, Leone G, Akahane M, Cevolani L, Tanzi P, Kido A, Honoki K, Tanaka Y, Donati DM. Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites. Eur J Orthop Surg Traumatol. 2017;27(6):813-9.
Gao ZH, Yin JQ, Xie XB, Zou CY, Huang G, wang J, Shen JN. Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement. BMC Musculoskelet Disord. 2014;15:330.
Harness NG, Mankin HJ. Giant-cell tumor of the distal forearm. J Hand Surg Am. 2004;29(2):188-93.
Jamshidi K, Bagherifard A, Mohaghegh MR, Mirzaei A. Fibular strut allograft or bone cement for reconstruction after curettage of a giant cell tumour of the proximal femur: a retrospective cohort study. Bone Joint J. 2022;104-B(2):297-301.
Jamshidi K, Sami S, Modares-Nejad HR, Jahansoz A. Local recurrence in giant cell tumor of bone: comparative study of two methods of surgical approach. J Res Med Sci. 2008;13:223-9.
Rishi R, Agarwal V, Sharma S, Agarwal R. Role of various treatment modality in GCT treatment. J Cardiovasc Dis Res. 2022;13:563-9.
Kafchitsas K, Habermann B, Proschek D, Kurth A, Eberhardt C. Functional results after giant cell tumor operation near knee joint and the cement radiolucent zone as indicator of recurrence. Anticancer Res. 2010;30(9):3795-9.
Colding-Rasmussen T, Horstmann PF, Jørgensen PH, Hettwer W, Hansen BH, Tierp-Wong CNE, Petersen MM. Does the use of polymethyl-methacrylate cement after intralesional curettage of giant cell tumors of appendicular bone guarantee reduced local recurrence rates? A retrospective analysis. J Orthop Surg (Hong Kong). 2023;31(3):10225536231202155.
Suzuki Y, Nishida Y, Yamada Y, Tsukushi S, Sugiura H, Nakashima H, Ishiguro N. Re-operation results in osteoarthritic change of knee joints in patients with giant cell tumor of bone. Knee. 2007;14(5):369-74.
Errani C, Tsukamoto S, Ciani G, Donati DM. Present day controversies and consensus in curettage for giant cell tumor of bone. J Clin Orthop Trauma. 2019;10(6):1015-20.
Vaishya R, Pokhrel A, Agarwal AK, Vijay V. Current status of bone cementing and bone grafting for giant cell tumour of bone: a systemic review. Ann R Coll Surg Engl. 2019;101(2):79-85.
Algawahmed H, Turcotte R, Farrokhyar F, Ghert M. High-speed burring with and without the use of surgical adjuvants in the intralesional management of giant cell tumor of bone: a systematic review and meta-analysis. Sarcoma. 2010;2010:586090.
Greenberg DD, Lee FY. Bisphosphonate-loaded bone cement as a local adjuvant therapy for giant cell tumor of bone: a 1 to 12-year follow-up study. Am J Clin Oncol. 2019;42(3):231-7.
Kundu ZS, Gupta V, Sangwan SS, Rana P. Curettage of benign bone tumors and tumor like lesions: a retrospective analysis. Indian J Orthop. 2013;47(3):295-301.
Yu X, Xu M, Xu S, Su Q. Clinical outcomes of giant cell tumor of bone treated with bone cement filling and internal fixation, and oral bisphosphonates. Oncol Lett. 2013;5(2):447-51.
Wada T, Kaya M, Nagoya S, Kawaguchi S, Isu K, Yamashita T, Yamawaki S, Ishii S. Complications associated with bone cementing for the treatment of giant cell tumors of bone. J Orthop Sci. 2002;7(2):194-8.
Arora M, Chan EK, Gupta S, Diwan AD. Polymethylmethacrylate bone cements and additives: a review of the literature. World J Orthop. 2013;4(2):67-74.
Duffy RK, Shafritz AB. Bone cement. J Hand Surg. 2011;36(6):1086-8.
Zheng Z, Chen S, Liu X, Wang Y, Bian Y, Feng B, Zhao R, Qiu Z, Sun Y, Zhang H, Cui F, Yang X, Weng X. A bioactive polymethylmethacrylate bone cement for prosthesis fixation in osteoporotic hip replacement surgery. Mater Des. 2021;209:109966.
Magnan B, Bondi M, Maluta T, Samaila E, Schirru L, Dall'Oca C. Acrylic bone cement: current concept review. Musculoskelet Surg. 2013;97(2):93-100.
Bistolfi A, Ferracini R, Albanese C, Vernè E, Miola M. PMMA-based bone cements and the problem of joint arthroplasty infections: status and new perspectives. Materials. 2019;12(23):4002.
Soleymani Eil Bakhtiari S, Bakhsheshi‐Rad HR, Karbasi S, Tavakoli M, Hassanzadeh Tabrizi SA, Ismail AF, Seifalian A, RamaKrishna S, Berto F. Poly (methyl methacrylate) bone cement, its rise, growth, downfall and future. Polym Int. 2021;70(9):1182-201.
Saleh KJ, El Othmani MM, Tzeng TH, Mihalko WM, Chambers MC, Grupp TM. Acrylic bone cement in total joint arthroplasty: a review. J Orthop Res. 2016;34(5):737-44.
Baldwin P, Li DJ, Auston DA, Mir HS, Yoon RS, Koval KJ. Autograft, allograft, and bone graft substitutes: clinical evidence and indications for use in the setting of orthopaedic trauma surgery. J Orthop Trauma. 2019;33(4):203-13.
Gillman CE, Jayasuriya AC. FDA-approved bone grafts and bone graft substitute devices in bone regeneration. Mater Sci Eng C Mater Biol Appl. 2021;130:112466.
Sohn HS, Oh JK. Review of bone graft and bone substitutes with an emphasis on fracture surgeries. Biomater Res. 2019;23:9.
Lobb DC, DeGeorge BR Jr, Chhabra AB. Bone graft substitutes: current concepts and future expectations. The J Hand Surg. 2019;44(6):497-505.e2.
Finkemeier CG. Bone-grafting and bone-graft substitutes. J Bone Joint Surg Am. 2002;84(3):454-64.
Khan SN, Cammisa FP Jr, Sandhu HS, Diwan AD, Girardi FP, Lane JM. The biology of bone grafting. J Am Acad Orthop Surg. 2005;13(1):77-86.